Pfizer ’s XELJANZ ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Stockwatch,
Company Website: https://www.pfizer.com NEW YORK -- (Business Wire) Pfizer Inc.
Company Website: https://www.pfizer.com NEW YORK -- (Business Wire) Pfizer Inc.
Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ (tofacitinib) 5 mg twice daily for…
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitin…
A A Teilen Drucken Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5…